Abstract
Inflammation is an important pathogenic mechanism in chronic heart failure (HF). The perpetuation of the inflammatory response in this syndrome may result either from excessive activation of proinflammatory cascades or disturbances in the resolution of inflammation. However, although cardiovascular research has extensively investigated the proinflammatory processes involved in chronic HF pathophysiology, the mechanisms responsible for inflammation resolution in this disease remain largely disregarded. The resolving response is currently considered an active process involving specific effectors that limit the progression of inflammation and promote tissue regeneration. This article aims at reviewing the major classes of lipid mediators of inflammation resolution, their cardiovascular, metabolic and renal protective effects that might putatively delay the onset and progression of chronic HF, and their therapeutic modulation. Furthermore, it also aims to emphasize the importance of adopting therapeutic strategies that stimulate the resolution of inflammation in chronic HF.
Keywords: Heart failure, resolution of inflammation, proresolving lipid mediators, cardiovascular/metabolic and renal protection, therapeutic modulation.
Current Drug Targets
Title:Resolving Inflammation in Heart Failure: Novel Protective Lipid Mediators
Volume: 17 Issue: 10
Author(s): Marta Reina-Couto, Luís Vale, Jorge Carvalho, Paulo Bettencourt, António Albino-Teixeira and Teresa Sousa
Affiliation:
Keywords: Heart failure, resolution of inflammation, proresolving lipid mediators, cardiovascular/metabolic and renal protection, therapeutic modulation.
Abstract: Inflammation is an important pathogenic mechanism in chronic heart failure (HF). The perpetuation of the inflammatory response in this syndrome may result either from excessive activation of proinflammatory cascades or disturbances in the resolution of inflammation. However, although cardiovascular research has extensively investigated the proinflammatory processes involved in chronic HF pathophysiology, the mechanisms responsible for inflammation resolution in this disease remain largely disregarded. The resolving response is currently considered an active process involving specific effectors that limit the progression of inflammation and promote tissue regeneration. This article aims at reviewing the major classes of lipid mediators of inflammation resolution, their cardiovascular, metabolic and renal protective effects that might putatively delay the onset and progression of chronic HF, and their therapeutic modulation. Furthermore, it also aims to emphasize the importance of adopting therapeutic strategies that stimulate the resolution of inflammation in chronic HF.
Export Options
About this article
Cite this article as:
Reina-Couto Marta, Vale Luís, Carvalho Jorge, Bettencourt Paulo, Albino-Teixeira António and Sousa Teresa, Resolving Inflammation in Heart Failure: Novel Protective Lipid Mediators, Current Drug Targets 2016; 17 (10) . https://dx.doi.org/10.2174/1389450117666160101121135
DOI https://dx.doi.org/10.2174/1389450117666160101121135 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diamidine Activity Against Trypanosomes: The State of the Art
Current Molecular Pharmacology Pulmonary Hemorrhage in Patients with Systemic Lupus Erythematosus
Current Respiratory Medicine Reviews Dipeptide Inhibitors of Thermolysin and Angiotensin I-Converting Enzyme
Current Topics in Medicinal Chemistry Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Advances and Progress in Chagas Disease Drug Discovery
Current Topics in Medicinal Chemistry Genistein as a Potential Anticancer Agent Against Head and Neck Squamous Cell Carcinoma
Current Topics in Medicinal Chemistry Virtual Screening-Based Discovery of Potent Hypoglycemic Agents: In Silico, Chemical Synthesis and Biological Study
Current Computer-Aided Drug Design Blocking the Path to Death: Anti-Apoptotic Molecules in Ischemia /Reperfusion Injury of the Liver
Current Pharmaceutical Design Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives
Current Stem Cell Research & Therapy Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Current Drug Targets Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Current Vascular Pharmacology Genetic Variation of Human Adrenergic Receptors: From Molecular and Functional Properties to Clinical and Pharmacogenetic Implications
Current Topics in Medicinal Chemistry Veno-Arterial Extracorporeal Membrane Oxygenation in the Adult: A Bridge to the State of the Art
Current Cardiology Reviews Subclassification and Nomenclature of α- and β-Adrenoceptors
Current Topics in Medicinal Chemistry Peroxisome Proliferator-Activated Receptors and the Control of Fatty Acid Oxidation in Cardiac Hypertrophy
Mini-Reviews in Medicinal Chemistry Clozapine Safety, 35 Years Later
Current Drug Safety Biomarkers of Oxidative Stress and Cataract. Novel Drug Delivery Therapeutic Strategies Targeting Telomere Reduction and the Expression of Telomerase Activity in the Lens Epithelial Cells with N-Acetylcarnosine Lubricant Eye Drops: Anti-Cataract which Helps to Prevent and Treat Cataracts in the Eyes of Dogs and other Animals
Current Drug Delivery Glucose Control and Use of Continuous Glucose Monitoring in the Intensive Care Unit: A Critical Review
Current Diabetes Reviews Editorial (Thematic Issue: Pharmacologic Strategies with Afterload Reduction in Low Cardiac Output Syndrome After Pediatric Cardiac Surgery)
Current Vascular Pharmacology